Ku ya 17 Ugushyingo 2025, Abbisko yatangaje ku rubuga rwa posteri igaragaza imikorere myiza y’igihe kirekire, umutekano n’ibyavuye mu bushakashatsi ku barwayi bwakozwe ku rwego rw’isi ku cyiciro cya gatatu cya MANEUVER kuri pimicotinib (ABSK021) ku barwayi barwaye kanseri y’uturemangingo twinshi (TGCT) mu nama ngarukamwaka ya Connective Tissue Oncology Society (CTOS) 2025.
Pimicotinib ni umuti mushya, unywa, utoranya cyane, kandi ukomeye wa CSF-1R inhibitor wakozwe ku giti cyawo na Abbisko Therapeutics. Ubushakashatsi bwa MANEUVER ni igerageza ry’ubuvuzi rya Phase III, rikorerwa mu nzego nyinshi, ryakozwe ku buryo butaziguye, ritabona kabiri, rigenzurwa na placebo rigizwe n’ibice bitatu, ryagenewe gusuzuma imikorere n’umutekano wa pimicotinib ku barwayi ba TGCT. Iherezo ry’ibanze n’iherezo ry’ingenzi ryose rya kabiri byagezweho mu Gice cya 1 mu cyumweru cya 25, kandi ibisubizo bihuye nabyo byatanzwe mu Nama Ngarukamwaka ya 2025 y’Umuryango w’Abanyamerika w’Ubuvuzi bw’Imiti (ASCO). Iherezo ry’ibanze ni igipimo cy’igisubizo (ORR) mu mpera z’Igice cya 1, nk’uko byasuzumwe na komite yigenga isuzuma ry’abatabona (BIRC) hakurikijwe RECIST v1.1. Mu Cyumweru cya 25, pimicotinib yagaragaje iterambere rikomeye muri ORR ugereranije na placebo mu Cyumweru cya 25 (54.0% ugereranije na 3.2%, P<0.0001).
Ibyavuye mu nama ngarukamwaka ya CTOS 2025 ni amakuru y’igihe kirekire ku mikorere n’umutekano byavuye mu kurangiza igice cya 2 cy’ubushakashatsi bwa MANEUVER. Hamwe n’ikurikirana ry’amezi 14.3, abarwayi bahawe pimicotinib kuva ubushakashatsi butangira bagaragaje ko bafite ubushobozi bwo guhangana n’ibibyimba bikomeye kandi biramba. ORR yakozwe na komite yigenga isuzuma ry’ibibyimba (BIRC) kuri RECIST v1.1 yiyongereye kuva kuri 54% mu cyumweru cya 25 igera kuri 76.2% (95% CI: 63.8, 86.0), aho abarwayi bane bakiriye neza.
Hagati aho, ubushakashatsi bwagaragaje kandi ko hakomeje gutera imbere mu buryo bufatika mu isuzuma ry’ibyavuye mu buvuzi (COAs) bijyanye n’ubuzima bw’abarwayi ba TGCT, harimo uburyo bagenda, gukomera, ububabare, n’imikorere y’umubiri. Iyi posita yanagaragaje inyungu z’ubuzima (QoL) zapimwe hifashishijwe EQ-5D-5L visual analog scale (VAS). Abarwayi bahabwaga ubuvuzi bwa pimicotinib bagaragaje ko impuzandengo ya QoL yazamutseho 7.4% ugereranije n’igihe cy’ibanze mu cyumweru cya 25, byazamutse bigera kuri 13.1% mu cyumweru cya 73.
Byongeye kandi, abarwayi babanje guhabwa umuti wa placebo mu gice cya 1 hanyuma bagahindurirwa pimicotinib mu gice cya 2 nabo babonye inyungu mu buvuzi, bagera kuri ORR ya 64.5% mu gihe cy'amezi 8.5 bakurikiranye, hamwe n'impinduka zigaragara muri COAs.
Ku bijyanye n'umutekano, ubukana bw'igipimo cyakoreshejwe bwakomeje kuba hejuru kuri 88.2% mu gihe cyo kuvurwa. Ingaruka mbi nyinshi zabayeho nyuma yo kuvurwa (TEAEs) zari mu cyiciro cya 1-2. Nta bimenyetso bishya by'umutekano byagaragaye, kandi nta bimenyetso byerekana uburozi bw'umwijima buterwa n'imiti, cyangwa uburozi bw'umusatsi/uruhu.
Ni ngombwa kumenya ko mu nama y’Umuryango w’Uburayi wita ku ndwara za kanseri (ESMO) ya 2025 yabaye mu Ukwakira uyu mwaka, Porofeseri Xiaohui Niu wo mu bitaro bya Beijing Jishuitan, umushakashatsi mukuru (PI) w’ubushakashatsi bwa MANEUVER, yatanze ibi byavuye mu bushakashatsi mu magambo.
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Indangamuntu ya WeChat: 17801183037
Email ①：myimmnet@163.com
Email ②：100085_010@163.com
Igihe cyo kohereza: Ugushyingo-18-2025